Univariate analysis of possible predictive factors for PFS and OS
| . | ORR . | PFS . | OS . | ||
|---|---|---|---|---|---|
| P . | P . | HR (95% CI) . | P . | HR (95% CI) . | |
| >65 y | .486 | .901 | 1.024 (0.545-1.993) | .81 | 1.105 (0.486-2.510) |
| Male | .705 | .315 | 1.415 (0.719-2.784) | .786 | 1.127 (0.476-2.669) |
| ≥3 lines of therapy | .144 | .830 | 1.079 (0.539-2.157) | .553 | 1.289 (0.557-2.981) |
| ≥4 lines of therapy | .855 | .651 | 0.859 (0.446-1.657) | .214 | 0.595 (0.262-1.351) |
| Creatinine clearance (≥50 mL/min) | .320 | .410 | 0.643 (0.225-1.837) | .418 | 2.296 (0.307-17.163) |
| Thrombocytes | .217 | .911 | 1.0 (0.995-1.005) | .209 | 1.004 (0.998-1.009) |
| β2-microgobulin | .697 | .050 | 1.122 (1.000-1.259) | .369 | 1.058 (0.935-1.197) |
| Albumin | .361 | .253 | 1.001 (0.999-1.003) | .147 | 1.002 (0.999-1.005) |
| LDH | .525 | .081 | 1.002 (1.000-1.004) | .001 | 1.004 (1.001-1.006) |
| High-risk cytogenetics | .705 | .816 | 0.912 (0.420-1.981) | .958 | 0.974 (0.367-2.584) |
| WHO 0+1 vs 2+3 | .010 | .867 | 0.932 (0.405-2.141) | .238 | 0.567 (0.222-1.453) |
| Len-refractory vs len- and bor-refractory disease | .103 | .376 | 0.736 (0.374-1.450) | .798 | 0.896 (0.386-2.078) |
| Full-dose lenalidomide (25 mg or equivalent in case of renal insufficiency) before start REP-therapy | 1.00 | .497 | 1.299 (0.610-2.765) | .950 | 1.031 (0.402-2.643) |
| REP directly after development of len-refractory disease | .861 | .951 | 1.02 (0.532-1.957) | .785 | 1.122 (0.491-2.568) |
| . | ORR . | PFS . | OS . | ||
|---|---|---|---|---|---|
| P . | P . | HR (95% CI) . | P . | HR (95% CI) . | |
| >65 y | .486 | .901 | 1.024 (0.545-1.993) | .81 | 1.105 (0.486-2.510) |
| Male | .705 | .315 | 1.415 (0.719-2.784) | .786 | 1.127 (0.476-2.669) |
| ≥3 lines of therapy | .144 | .830 | 1.079 (0.539-2.157) | .553 | 1.289 (0.557-2.981) |
| ≥4 lines of therapy | .855 | .651 | 0.859 (0.446-1.657) | .214 | 0.595 (0.262-1.351) |
| Creatinine clearance (≥50 mL/min) | .320 | .410 | 0.643 (0.225-1.837) | .418 | 2.296 (0.307-17.163) |
| Thrombocytes | .217 | .911 | 1.0 (0.995-1.005) | .209 | 1.004 (0.998-1.009) |
| β2-microgobulin | .697 | .050 | 1.122 (1.000-1.259) | .369 | 1.058 (0.935-1.197) |
| Albumin | .361 | .253 | 1.001 (0.999-1.003) | .147 | 1.002 (0.999-1.005) |
| LDH | .525 | .081 | 1.002 (1.000-1.004) | .001 | 1.004 (1.001-1.006) |
| High-risk cytogenetics | .705 | .816 | 0.912 (0.420-1.981) | .958 | 0.974 (0.367-2.584) |
| WHO 0+1 vs 2+3 | .010 | .867 | 0.932 (0.405-2.141) | .238 | 0.567 (0.222-1.453) |
| Len-refractory vs len- and bor-refractory disease | .103 | .376 | 0.736 (0.374-1.450) | .798 | 0.896 (0.386-2.078) |
| Full-dose lenalidomide (25 mg or equivalent in case of renal insufficiency) before start REP-therapy | 1.00 | .497 | 1.299 (0.610-2.765) | .950 | 1.031 (0.402-2.643) |
| REP directly after development of len-refractory disease | .861 | .951 | 1.02 (0.532-1.957) | .785 | 1.122 (0.491-2.568) |
CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase.